Sign in to view content

Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study

Peter K. Kaiser, MD FASRS

Video
Published 2019

Peter K. Kaiser, MD

AMD Non-neovascular Symposium

Related

Staring a Clinical Trials Program
David A. Eichenbaum, MD, FASRS
Updates from the Field
2019
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Impact of Baseline OCT Characteristics on Response to Risuteganib for the Treatment of Intermediate Age-Related Macular Degeneration
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more